Table III.
Glucose–insulin homeostasis: patient characteristics at baseline and after 3 months of treatment
| Parameter | Group M | Group O | Treatment difference p < 0.05 | ||||
|---|---|---|---|---|---|---|---|
| Baseline | After treatment | Change | Baseline | After treatment | Change | ||
| Glucose 0 [mmol/l] | 5.56 ±0.78 | 5.65 ±0.72 | 0.09 ±0.69 | 5.23 ±0.72 | 5.54 ±0.82 | 0.31 ±1.06 | NS |
| Glucose 120 [mmol/l] | 7.60 ±1.61 | 7.46 ±1.21 | –0.14 ±1.76 | 7.16 ±2.35 | 6.96 ±1.22 | –0.20 ±2.24 | NS |
| Insulin 0 [mU/l] | 19.9 ±19.1 | 17.3 ±15.7 | –2.5 ±13.8 | 11.9 ±5.7 | 9.5 ±5.5 | –2.4 ±3.6 | NS |
| Insulin 120 [mU/l] | 101.5 ±65.6 | 83.9 ±56.1 | –18.8 ±40.2* | 78.5 ±62.1 | 60.0 ±54.8 | –19.0 ±50.5* | NS |
| HOMA-IR | 3.31 ±1.98 | 2.96 ±1.90 | –0.38 ±2.56 | 2.81 ±1.39 | 2.23 ±1.28 | –0.58 ±0.96 | NS |
| ISI Matsuda | 53.8 ±10.8 | 38.5 ±12.5 | 17.5 ±47.4* | 99.3 ±10.5 | 80.5 ±10.1 | 18.6 ±10.3* | NS |
Data are presented as mean ± SD. * Statistically significant differences (p < 0.05) between the initial and final values. M – metformin group, O – orlistat group, HOMA-IR – homeostatic model assessment-insulin resistance, ISI – insulin sensitivity index.